AA
ARRY

ALPS Advisors’s Array Biopharma Inc ARRY Stock Holding History

ALPS Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-382,739
Closed -$9.33M – 911
2019
Q1 		$9.33M Sell
382,739
-109,688
-22% -$2.28M 0.07% 124
2018
Q4 		$7.02M Buy
492,427
+117,857
+31% +$1.79M 0.05% 133
2018
Q3 		$5.69M Buy
374,570
+70,370
+23% +$1.08M 0.04% 155
2018
Q2 		$5.1M Buy
304,200
+25,712
+9% +$409K 0.03% 168
2018
Q1 		$4.54M Buy
278,488
+60,160
+28% +$964K 0.04% 155
2017
Q4 		$2.79M Buy
218,328
+49,485
+29% +$563K 0.02% 170
2017
Q3 		$2.08M Buy
168,843
+14,673
+10% +$136K 0.01% 185
2017
Q2 		$1.29M Buy
+154,170
New +$1.26M 0.01% 206

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ALPS Advisors's ARRY Position: Q2 2019 in Review

ALPS Advisors sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 382,739 shares — an estimated $9.33M sold.

ALPS Advisors first reported a position in ARRY in Q2 2017 and held it in 8 quarters. The position peaked at $9.33M in Q1 2019. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • ALPS Advisors reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • ALPS Advisors sold 382,739 Array Biopharma Inc shares in Q2 2019, an estimated $9.33M.
  • ALPS Advisors first reported a position in Array Biopharma Inc in Q2 2017 and held it in 8 quarters.
  • ALPS Advisors's Array Biopharma Inc position peaked at $9.33M in Q1 2019.
  • 318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on ALPS Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.